HbA1c non-fasting range is one of the most searched topics by people managing or monitoring their blood glucose in the UK — and for good reason. The HbA1c test, which measures average blood glucose over the preceding two to three months, requires no fasting beforehand, making it far more convenient than a fasting plasma glucose test. Whether you have received a result and want to understand what it means, or you are preparing for a routine diabetes review, this guide explains the UK reference ranges, what can affect your reading, and what steps to take if your result falls outside the normal range.

What Is HbA1c and Why Fasting Is Not Required

HbA1c requires no fasting because it measures the cumulative attachment of glucose to haemoglobin over two to three months, not the glucose level at a single point in time.

HbA1c, or glycated haemoglobin, is a blood test that measures the average blood glucose level over the preceding two to three months. It works by detecting the proportion of haemoglobin — the oxygen-carrying protein found in red blood cells — that has glucose molecules attached to it. Because red blood cells have a lifespan of approximately 120 days, the HbA1c result reflects a sustained average rather than a single moment in time, making it a highly reliable marker for long-term blood glucose control.

One of the most important practical advantages of the HbA1c test is that fasting is not required. Unlike a fasting plasma glucose test, which demands that a patient abstains from food and drink (other than water) for at least eight hours beforehand, the HbA1c can be taken at any time of day, regardless of when the patient last ate. This is because the test measures a cumulative biological process — the gradual attachment of glucose to haemoglobin — rather than the glucose circulating in the bloodstream at a specific moment.

This non-fasting nature makes HbA1c particularly convenient for both patients and clinicians. Appointments do not need to be scheduled first thing in the morning, and patients do not need to alter their eating habits before attending. According to NICE guideline NG28 (Type 2 diabetes in adults: management) and NHS guidance, HbA1c is the preferred diagnostic and monitoring tool for type 2 diabetes in most adults, precisely because of its practicality and reproducibility. It is measured as a percentage or in millimoles per mole (mmol/mol), with the latter being the standard unit used across UK laboratories.

However, HbA1c is not appropriate for diagnosing diabetes in all situations. It should not be used as a diagnostic test in the following circumstances:

• Suspected type 1 diabetes (where urgent clinical assessment and alternative tests are required)

• Children and young people

• Pregnancy or within approximately two to three months postpartum

• Acute illness, where blood glucose may be transiently elevated

• Conditions causing significant anaemia, haemoglobin variants, or altered red blood cell turnover

In these situations, alternative tests such as fasting plasma glucose or an oral glucose tolerance test (OGTT) should be used, and clinical advice sought promptly.

Understanding HbA1c Reference Ranges in the UK

In the UK, an HbA1c below 42 mmol/mol is normal, 42–47 mmol/mol indicates prediabetes, and 48 mmol/mol or above meets the WHO 2011 diagnostic threshold for type 2 diabetes.

In the United Kingdom, HbA1c results are reported in mmol/mol in line with the International Federation of Clinical Chemistry (IFCC) standardisation, though some older references may still cite percentage values. Understanding what these numbers mean is essential for interpreting your result correctly.

The broadly accepted reference ranges used in UK clinical practice are as follows:

• Below 42 mmol/mol (6.0%) — considered normal; no indication of diabetes or prediabetes

• 42–47 mmol/mol (6.0–6.4%) — classified as non-diabetic hyperglycaemia (prediabetes); indicates an elevated risk of developing type 2 diabetes

• 48 mmol/mol (6.5%) or above — meets the WHO 2011 diagnostic criteria for type 2 diabetes in adults, provided the result is confirmed on a second occasion in the absence of symptoms (or once if symptoms are present)

These thresholds are aligned with NICE guideline NG28 and WHO 2011 diagnostic criteria, both of which are adopted across NHS England, Scotland, Wales, and Northern Ireland.

It is important to note that HbA1c at this threshold does not diagnose suspected type 1 diabetes, which requires urgent clinical assessment and is typically confirmed using additional tests (such as C-peptide and diabetes-specific autoantibodies). HbA1c is also not used for diagnosis in children and young people, during pregnancy, in acute illness, in the early postpartum period, or where significant anaemia, haemoglobin variants, or conditions affecting red blood cell turnover are present. In these circumstances, fasting plasma glucose or OGTT should be considered.

For people already diagnosed with type 2 diabetes, NICE NG28 recommends:

• An HbA1c target of 48 mmol/mol (6.5%) for those managed by lifestyle measures or a single non-hypoglycaemic drug

• 53 mmol/mol (7.0%) for those on medications that carry a risk of hypoglycaemia, such as sulphonylureas or insulin

Targets should be individualised based on age, comorbidities, frailty, and patient preference. It is also worth noting that NICE recommends considering an SGLT-2 inhibitor (such as empagliflozin, dapagliflozin, or canagliflozin) as a priority treatment option — often alongside or instead of metformin where not tolerated or contraindicated — for people with type 2 diabetes who have established cardiovascular disease, heart failure, or chronic kidney disease, given the additional cardiorenal protective benefits of this drug class.

Factors That Can Affect Your HbA1c Reading

Haemolytic anaemia, iron deficiency, haemoglobin variants, and certain medications such as corticosteroids or SGLT-2 inhibitors can falsely alter HbA1c results, making alternative tests necessary in some cases.

Although HbA1c is considered a robust and reliable test, several physiological and clinical factors can influence the result, potentially leading to falsely elevated or falsely lowered readings. Clinicians should be aware of these variables when interpreting results, particularly where HbA1c does not appear consistent with the clinical picture or self-monitored blood glucose readings. Where HbA1c is considered unreliable, alternative tests such as fasting plasma glucose, OGTT, or fructosamine should be considered.

Conditions that may falsely lower HbA1c include:

• Haemolytic anaemia (increased red blood cell destruction shortens their lifespan)

• Iron deficiency anaemia treated with iron supplementation (accelerated red cell production)

• Recent blood transfusion

• Haemoglobin variants such as HbS (sickle cell) or HbC — note that the degree of interference depends on the specific assay used; local laboratory guidance should be consulted

• Chronic kidney disease (due to altered red cell survival)

• Erythropoietin (EPO) therapy or haemodialysis (which alter red cell turnover)

• HIV/antiretroviral therapy (certain antiretrovirals may affect red cell lifespan)

Conditions that may falsely raise HbA1c include:

• Iron deficiency anaemia (before treatment, due to reduced red cell turnover)

• Vitamin B12 or folate deficiency

• Splenectomy (prolonged red cell lifespan)

• Certain haemoglobin variants, depending on the assay used

Where haemoglobin variants are suspected, clinicians are advised to consult their local laboratory or UK pathology guidance (such as RCPath recommendations) regarding assay-specific interference, and to use an alternative diagnostic method if appropriate.

Beyond haematological factors, ethnicity may also play a role. Some studies suggest that individuals of South Asian, African, or Afro-Caribbean descent may have slightly higher HbA1c values at equivalent blood glucose levels compared to white European populations. This is an area of ongoing research, and no official adjustment is currently recommended in UK guidelines.

Lifestyle factors such as diet, physical activity, and medication adherence directly influence blood glucose control and therefore legitimately affect HbA1c. Certain medications — including corticosteroids (which raise blood glucose) and SGLT-2 inhibitors or GLP-1 receptor agonists (which lower it) — will also be reflected in the result. Always inform your healthcare team of any recent changes to your medication or health status before your test.

If you experience any suspected side effects from your diabetes medicines — including symptoms of low blood sugar (hypoglycaemia) — you or your healthcare professional can report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

What to Do If Your HbA1c Result Is Outside the Normal Range

A result of 42–47 mmol/mol warrants structured lifestyle intervention and annual monitoring; 48 mmol/mol or above usually requires a confirmatory second test before a diagnosis of type 2 diabetes is made.

Receiving an HbA1c result outside the normal range can feel concerning, but it is important to understand that a single result is rarely acted upon in isolation. Your GP or practice nurse will interpret the result alongside your symptoms, medical history, risk factors, and any other relevant investigations before making any clinical decisions.

If your result falls in the non-diabetic hyperglycaemia range (42–47 mmol/mol): This is an important opportunity for early intervention. NICE recommends that individuals in this range be offered structured lifestyle support, including guidance on diet, physical activity, and weight management. The NHS Diabetes Prevention Programme (NHS DPP) is available across England and offers evidence-based support to help reduce the risk of progression to type 2 diabetes. Equivalent structured lifestyle programmes are available in Scotland (through NHS Scotland), Wales (Diabetes Prevention Programme Wales), and Northern Ireland — your GP can advise on local referral pathways. Your GP will typically recommend a repeat HbA1c test at 12 months, or sooner (for example, at around six months) if your result is close to the diagnostic threshold of 48 mmol/mol or if your clinical circumstances change.

If your result is 48 mmol/mol or above: A confirmatory second test is usually required unless you have clear symptoms of diabetes (such as excessive thirst, frequent urination, or unexplained weight loss), in which case a single result may be sufficient for diagnosis. Following confirmation, your GP will discuss a management plan that may include lifestyle changes, blood glucose monitoring, and medication. Metformin remains the standard first-line pharmacological treatment for most people with type 2 diabetes, as recommended by NICE NG28. However, for people with established cardiovascular disease, heart failure, or chronic kidney disease, NICE recommends considering an SGLT-2 inhibitor as a priority option, given its additional cardiorenal benefits.

When to seek urgent or same-day medical assessment:

• You have symptoms of high blood sugar (polydipsia, polyuria, fatigue, blurred vision) together with rapid weight loss, vomiting, or signs of ketones in your urine or breath — these may indicate type 1 diabetes or diabetic ketoacidosis, which requires same-day assessment

• Your result has risen significantly since your last test

• You are pregnant or planning to become pregnant

• You have concerns about your result or your current management plan

Monitoring frequency: For people on treatment for type 2 diabetes, NICE recommends measuring HbA1c every three to six months until levels are stable, then every six months thereafter. For those at risk (non-diabetic hyperglycaemia), annual monitoring is standard, with more frequent checks if clinically indicated.

Staying engaged with your healthcare team and attending routine reviews is the most effective way to maintain good long-term health outcomes. If you experience any suspected side effects from your diabetes medicines — including symptoms of hypoglycaemia such as shakiness, sweating, or confusion — report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions